Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Mov Disord. 2010 Oct 19;26(1):100–106. doi: 10.1002/mds.23401
Stock Ownership in medically-
related fields
None		 Intellectual Property Rights
Licenses
  1. Murine monoclonal anti-[rat D1a dopamine receptor] antibody (SG2-D1a).
  2. Murine monoclonal anti-[rat D1b dopamine receptor] antibody (SG4-D1b).

Chemicon International Inc. (Millipore) 2000
Santa Cruz 2005
Affinity BioReagents (ABR) 2006
Novus Biological 2007
Invitrogen (D1a only) 2007
Consultancies
None		 Expert Testimony
none
Advisory Boards
None 		Employment
none
Partnerships
None		 Contracts
none
Honoraria
None		 Royalties
See licenses approx $1,100
Grants
NIH/NIDA: R01 DA024675-01A2
Development Of Dopamine D3
Ligands As Medications For
Psychostimulant Addicton
R.R. Luedtke Co-Investigator
from 12/09 to 11/12		 Other
None